NCT04643886.

Study name	A multiple dose study of repeat intravitreal injections of GEM103 in dry age‐related macular degeneration
Methods	Phase 2a, open‐label, multiple dose study at multiple centres
Participants	Adults 50 years and older with GA due to AMD and BCVA of 24 to 83 letters on the ETDRS chart. All participants must have one of the two pre‐specified genetic profiles. Participants with prior history of exudative AMD or CNV are excluded.
Interventions	GEM103 administered as repeat intravitreal injections in participants with Genetic Profile A as compared to participants with Genetic Profile B
Outcomes	Primary outcome measure: Safety of IVT injections of GEM103, as measured by number of participants with ocular adverse events (time frame: 18 months) Secondary outcome measures: Change in BCVA as assessed by ETDRS chart (time frame: 6 months) Total CFH levels in aqueous humour after GEM103 IVT injection (time frame: 6 months)
Starting date	November 2020
Contact information	Gemini Therapeutics Inc., MA, USA
Status	Terminated (no further benefit)
Required reporting date	February 2023
Notes	—